Prodrugs of riluzole and their method of use

A method for treating melanoma, said method comprising administering to a subject an effective amount of

• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is OR2,
• R2 is selected from the group consisting of optionally substituted C3-C6 alkyl and CH2(CH2)nNR8aR8b,
• R8a is optionally substituted C1-C6 alkyl,
• R8b is optionally substituted C2-C6 alkyl, and
• n is 1 or 2;
• or
• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is CH2CH2CO2R4, and
• R4 is selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
• or
• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is CH2CH2CONHR5,
• R5 is selected from the group consisting of hydrogen, optionally substituted C1-C6 Alkyl, CH2CH2NR10aR10b, and CH2R11,
• R10a and R10b are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing an oxygen,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing two nitrogen atoms, and
• R11 is selected from the group consisting of optionally substituted phenyl and optionally substituted heteroaryl.

A composition comprising an effective amount of

• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is OR2,
• R2 is selected from the group consisting of optionally substituted C3-C6 alkyl and CH2(CH2)nNR8aR8b,
• R8a is optionally substituted C1-C6 alkyl,
• R8b is optionally substituted C2-C6 alkyl, and
• n is 1 or 2;
• or
• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is CH2CH2CO2R4, and
• R4 is selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
• or
• at least one compound having formula (I) below:
• including hydrates, solvates, pharmaceutically acceptable salts, and complexes thereof, wherein:
• R1 is CH2CH2CONHR5,
• R5 is selected from the group consisting of hydrogen, optionally substituted C1-C6 Alkyl, CH2CH2NR10aR10b, and CH2R11,
• R10a and R10b are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing an oxygen,
• or
• R10a and R10b are taken together with the atom to which they are bound to form an optionally substituted ring having 5 to 6 ring atoms containing two nitrogen atoms, and
• R11 is selected from the group consisting of optionally
• substituted phenyl and optionally substituted heteroaryl.